Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

Impact · against what's priced in

The price action for Moderna is driven by mechanical index flows rather than fundamental shifts, as the oncology success was already baked into the valuation. BioNTech and Pfizer see marginal gains from sector strength, but no new catalysts have emerged to alter their current valuations.

BNTX+0.00

Doesn't touch the price's assumptions

In context

The 3% rise is attributed to general sector strength and its mRNA platform, but provides no new data on the lung cancer pipeline or financials that would shift the current price.